Additional dexamethasone improves the response rate among patients with multiple myeloma treated with single agent bortezomib.
Cavenagh
Jamie D
JD
Department of Hematology, St. Bartholomew's Hospital, West Smithfield, London, UK. j.d.cavenagh@qmul.ac.uk
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003907:Dexamethasone / Q000627:therapeutic use*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D012074:Remission Induction / Q000379:methods
D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone